Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

European Partners Combine to Bring Therapeutic Antibody to Market

By BiotechDaily International staff writers
Posted on 15 Aug 2013
Two European biotechnology companies have agreed to collaborate to complete development and commence marketing of a novel therapeutic antibody that targets the GD2 antigen, which is abundantly expressed on neuroblastoma cells.

Neuroblastoma is a cancer of the sympathetic nervous system that accounts for about 7% of all childhood cancers and 10% to 15% of all childhood cancer deaths.

Apeiron Biologics AG (Vienna, Austria), a biotech company focused on immunologic and biologic therapies against cancer, has agreed to a joint project with Rentschler Biotechnologie GmbH (Laupheim, Germany), a full service biopharmaceutical contract manufacturer, to complete development of the chimeric APN311 antibody for advanced clinical studies and then to manufacture it under full GMP compliance.

Per the agreement, Apeiron will receive access to experienced teams, appropriate mammalian cell culture capacity for clinical phase I to III trials, commercial production, fill and finish services as well as a scientifically driven, and responsive project management. The manufacturing process, validation, and regulatory affairs will be transferred to Rentschler.

Hans Loibner, CEO of Apeiron Biologics, said, "We are happy to have identified Rentschler as a professional contract manufacturer and consider this collaboration as a distinct value increase for our project APN311, which is also acknowledged in discussions with existing and potential partners. This decision resolved a significant hurdle in our effort to make this therapy available as soon as possible. I am very much looking forward to a fruitful collaboration."

"We are very excited to contribute our expertise to meet the truly challenging timeline of this project which is so very important for children suffering from this life threatening disease," said Frank Ternes, chief business officer at Rentschler. "We are confident that this cooperative atmosphere will continue to grow and mature over the course of the entire project, and ensure the success of this partnership."

Related Links:
Apeiron Biologics AG
Rentschler Biotechnologie GmbH



Channels

Genomics/Proteomics

view channel
Image: An adult cardiomyocyte has re-entered the cell cycle after expression of miR302-367 (Photo courtesy of the laboratory of Dr. Edward Morrisey, University of Pennsylvania).

Certain MicroRNAs Stimulate Regeneration of Adult Heart Tissue

Cardiac disease researchers working with a mouse model have discovered that by inducing a subset of microRNAs (miRNAs) that are active during development but silenced in the adult they could cause damaged... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.